Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Glioma 4Prostatic Neoplasms 3Astrocytoma 3Lung Neoplasms 2Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Ependymoma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 2Etoposide 2Erlotinib Hydrochloride 2pomalidomide 1dostarlimab 1dinutuximab 1cemiplimab 1bempegaldesleukin 1abemaciclib 1Valacyclovir 1Radiotherapy 1Radiation 1Prodrugs 1Pemetrexed 1ONC206 1Nivolumab 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fentanyl 1Cyclophosphamide 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ependymoma × Valacyclovir × Clear all
NCT00634231 2023-08-25

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Candel Therapeutics, Inc.

Phase 1 Completed
8 enrolled
CNS

Astrocytoma, Ependymoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡